SELLAS Life Sciences Group Inc. [NASDAQ: SLS] gained 12.38% on the last trading session, reaching $11.71 price per share at the time. The company report on March 11, 2021 that SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in the Emerging Growth Virtual Conference hosted by M Vest LLC and Maxim Group, LLC on Wednesday, March 17, 2021.
In addition to the SELLAS corporate presentation, Dr. Stergiou will participate in the Cancer Vaccines Panel hosted by Jason McCarthy, PhD, Maxim Senior Managing Director, Biotechnology (Research Analyst) on Wednesday, March 17 at 1:00 p.m. ET. The panel will be an informative discussion on the market opportunity for cancer vaccines as well as upcoming milestones from the participating companies.
SELLAS Life Sciences Group Inc. represents 14.19 million in outstanding shares, while the company has a total market value of $132.32 million with the latest information. SLS stock price has been found in the range of $10.1724 to $12.18.
If compared to the average trading volume of 2.13M shares, SLS reached a trading volume of 1272524 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about SELLAS Life Sciences Group Inc. [SLS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLS shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for SELLAS Life Sciences Group Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 01, 2018. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 02, 2018, representing the official price target for SELLAS Life Sciences Group Inc. stock. Previously, the target price had yet another raise to $13, while Maxim Group analysts kept a Buy rating on SLS stock.
The Average True Range (ATR) for SELLAS Life Sciences Group Inc. is set at 1.10 The Price to Book ratio for the last quarter was 12.46, with the Price to Cash per share for the same quarter was set at 0.73.
Trading performance analysis for SLS stock
SELLAS Life Sciences Group Inc. [SLS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.55. With this latest performance, SLS shares gained by 15.83% in over the last four-week period, additionally plugging by 457.62% over the last 6 months – not to mention a rise of 543.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLS stock in for the last two-week period is set at 65.50, with the RSI for the last a single of trading hit 69.41, and the three-weeks RSI is set at 63.12 for SELLAS Life Sciences Group Inc. [SLS]. The present Moving Average for the last 50 days of trading for this stock 8.05, while it was recorded at 10.66 for the last single week of trading, and 4.54 for the last 200 days.
SELLAS Life Sciences Group Inc. [SLS]: A deeper dive into fundamental analysis
Return on Total Capital for SLS is now -297.85, given the latest momentum, and Return on Invested Capital for the company is -344.59. Return on Equity for this stock declined to -344.59, with Return on Assets sitting at -111.78. When it comes to the capital structure of this company, SELLAS Life Sciences Group Inc. [SLS] has a Total Debt to Total Equity ratio set at 3.56. Additionally, SLS Total Debt to Total Capital is recorded at 3.44, with Total Debt to Total Assets ending up at 1.31.
Reflecting on the efficiency of the workforce at the company, SELLAS Life Sciences Group Inc. [SLS] managed to generate an average of -$3,907,000 per employee.SELLAS Life Sciences Group Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.20.
SELLAS Life Sciences Group Inc. [SLS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, SELLAS Life Sciences Group Inc. posted -2.68/share EPS, while the average EPS was predicted by analysts to be reported at -1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -168.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLS.
An analysis of insider ownership at SELLAS Life Sciences Group Inc. [SLS]
There are presently around $11 million, or 13.30% of SLS stock, in the hands of institutional investors. The top three institutional holders of SLS stocks are: VANGUARD GROUP INC with ownership of 577,064, which is approximately 327.113% of the company’s market cap and around 1.20% of the total institutional ownership; BLACKROCK INC., holding 100,424 shares of the stock with an approximate value of $1.18 million in SLS stocks shares; and EQUITABLE HOLDINGS, INC., currently with $1.1 million in SLS stock with ownership of nearly 56.385% of the company’s market capitalization.
Positions in SELLAS Life Sciences Group Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 13 institutional holders increased their position in SELLAS Life Sciences Group Inc. [NASDAQ:SLS] by around 561,058 shares. Additionally, 4 investors decreased positions by around 252,801 shares, while 5 investors held positions by with 111,291 shares. The mentioned changes placed institutional holdings at 925,150 shares, according to the latest SEC report filing. SLS stock had 9 new institutional investments in for a total of 84,144 shares, while 2 institutional investors sold positions of 225,117 shares during the same period.